{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:22:24Z","timestamp":1775841744416,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009891","name":"International Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1053\/j.ackd.2021.07.006","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T12:03:35Z","timestamp":1645185815000},"page":"429-437.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunotherapy-Related Acute Kidney Injury"],"prefix":"10.1053","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-7862","authenticated-orcid":false,"given":"Sandhya","family":"Manohar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.ackd.2021.07.006_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy--revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.006_bib3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"10.1053\/j.ackd.2021.07.006_bib5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2021.07.006_bib6","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors","volume":"Feb 6","author":"Garcia-Carro","year":"2021","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2021.07.006_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox Study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.ackd.2021.07.006_bib8","article-title":"Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort","volume":"Sep 17","author":"Stein","year":"2020","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Munoz","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.006_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10157-020-02008-1","article-title":"Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study","volume":"25","author":"Shimamura","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in Lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2021.07.006_bib12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib15","doi-asserted-by":"crossref","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.006_bib16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ekir.2020.05.027","article-title":"Immune check point inhibitor-associated endothelialitis","volume":"5","author":"Bobart","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ackd.2021.07.006_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.006_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ackd.2021.07.006_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib23","doi-asserted-by":"crossref","first-page":"e001287","DOI":"10.1136\/jitc-2020-001287","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1053\/j.ackd.2021.07.006_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in cancer immunotherapy: from Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"issue":"Suppl 7","key":"10.1053\/j.ackd.2021.07.006_bib27","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6538","key":"10.1053\/j.ackd.2021.07.006_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.abd1329","article-title":"Recruiting T cells in cancer immunotherapy","volume":"372","author":"Yost","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1053\/j.ackd.2021.07.006_bib29","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.ackd.2021.07.006_bib30","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities Elicted by CTLA-4 blockade in cancer patients are associated with early Diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a Multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2021.07.006_bib33","doi-asserted-by":"crossref","first-page":"e1349587","DOI":"10.1080\/2162402X.2017.1349587","article-title":"Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1\/PD-L1 blockade","volume":"6","author":"Zha","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/23993693211004612","article-title":"Phospholipase A2 receptor antibody mediated membranous nephropathy associated with cemiplimab","volume":"5","author":"Marco Bonilla","year":"2021","journal-title":"J Onco-Nephrology"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published Case Reports","volume":"9","author":"Cheema","year":"2018","journal-title":"World J Oncol"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.006_bib36","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.006_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related oxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.006_bib38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jama.2020.17308","article-title":"Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy","volume":"325","author":"Reid","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1053\/j.ackd.2021.07.006_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis","volume":"66","author":"von Itzstein","year":"2020","journal-title":"Clin Chem"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik B","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.ackd.2021.07.006_bib41","doi-asserted-by":"crossref","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-alpha and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10637-017-0524-2","article-title":"Radiomics to predict immunotherapy-induced pneumonitis: proof of concept","volume":"36","author":"Colen","year":"2018","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.kint.2018.11.009","article-title":"Interstitial nephritis in immune checkpoint inhibitor therapy","volume":"96","author":"Manohar","year":"2019","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2021.07.006_bib44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls D","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.006_bib45","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-Dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2021.07.006_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Transl Med"},{"issue":"17","key":"10.1053\/j.ackd.2021.07.006_bib47","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ackd.2021.07.006_bib48","author":"Oncology"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib50","first-page":"16","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy","volume":"360","author":"Manohar","year":"2020","journal-title":"Single Cent experience Manag Drug rechallenge Kidney"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib51","doi-asserted-by":"crossref","first-page":"e002292","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib52","doi-asserted-by":"crossref","first-page":"e000750","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1053\/j.ackd.2021.07.006_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12882-020-02044-9","article-title":"Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report","volume":"21","author":"Hultin","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ackd.2021.07.006_bib55","article-title":"Immune-checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","author":"Abhijat Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.006_bib56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.ackd.2021.07.006_bib57","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.ackd.2021.07.006_bib58","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.006_bib59","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.006_bib62","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: Past, present and Future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.006_bib63","first-page":"365","article-title":"Antitumor effects of interferon preparations in mice","volume":"45","author":"Gresser","year":"1970","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.006_bib64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"issue":"26","key":"10.1053\/j.ackd.2021.07.006_bib65","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.006_bib66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CJI.0b013e31821dcb50","article-title":"Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome","volume":"34","author":"Samlowski","year":"2011","journal-title":"J Immunother"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.006_bib67","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.ackd.2021.07.006_bib68","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1200\/JCO.1990.8.11.1839","article-title":"Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion","volume":"8","author":"Shalmi","year":"1990","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.ackd.2021.07.006_bib69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s002620050582","article-title":"The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells","volume":"48","author":"Kruit","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.ackd.2021.07.006_bib70","series-title":"Principles and practice of the biologic therapy of cancer","first-page":"916","author":"Rosenberg","year":"2000"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib71","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/ndt\/16.4.846","article-title":"Renal thrombotic microangiopathy induced by interferon-alpha","volume":"16","author":"Badid","year":"2001","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.006_bib72","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/08860229309054974","article-title":"Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia","volume":"15","author":"Stratta","year":"1993","journal-title":"Ren Fail"},{"issue":"9","key":"10.1053\/j.ackd.2021.07.006_bib73","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1938::AID-CNCR9>3.0.CO;2-M","article-title":"Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy","volume":"83","author":"Shah","year":"1998","journal-title":"Cancer"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:05:16Z","timestamp":1761548716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559521000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1548559521000550"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2021.07.006","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy-Related Acute Kidney Injury","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}